Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU CHMP Finalizes Outstanding Issues On Aimovig And Symproic

Executive Summary

EU regulators meeting in London are finalizing the outstanding questions they have for companies whose products are approaching the final stages of the approval process.

You may also be interested in...



Asia Deal Watch: Shionogi Finds Commercial Partners For Symproic In US, Europe

Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.

Volanesorsen, Inotersen And Erenumab Nearing End Of EU Review Process

Some 17 products are in the late stages of evaluation at the European Medicines Agency, including half a dozen orphans, a handful of other new drugs, and a clutch of biosimilars.

Volanesorsen, Inotersen And Erenumab Nearing End Of EU Review Process

Some 17 products are in the late stages of evaluation at the European Medicines Agency, including half a dozen orphans, a handful of other new drugs, and a clutch of biosimilars.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel